Erdosteine , ≥98.0% , 84611-23-4

CAS NO.：84611-23-4

Empirical Formula: C8H11NO4S2

Molecular Weight: 249.31

MDL number: MFCD00867664

EINECS: 642-172-5

PRODUCT Properties

• Melting point: 156-160°C
• Boiling point: 590.4±50.0 °C(Predicted)
• Density: 1.48±0.1 g/cm3(Predicted)
• storage temp.: Sealed in dry,2-8°C
• solubility: Acetonitrile (Slightly), DMSO (Slightly), Methanol (Slightly)
• pka: 3.71(at 25℃)
• form: Solid
• color: White to Off-White
• λmax: 236nm(H2O)(lit.)
• Merck: 14,3647
• InChIKey: QGFORSXNKQLDNO-UHFFFAOYSA-N

Description and Uses

Erdosteine is a new expectorant introduced in France for the treatment of chronic bronchitis. Erdosteine possesses mucomodulator, mucolytic, mucokinetic and free radical scavenging properties. Its therapeutic efficacy has been demonstrated in patients affected by congestion and viscous mucus in higher and lower respiratory tracts as in acute and chronic bronchitis, sinusitis, otitis, tracheopharyngitis and coryza. Erdosteine acts through its active metabolites containing free sulfhydryl groups which are able to depolymerize the mucopolysaccharides of the excreatum by breaking the disulfide linkages (thereby lowing its viscosity). The prodrug approach provides unique characteristics to erdosteine by offering stable therapeutic efficacy and prevention of the gastric mucus from lythic phenomena. The agent was also reported to have local antiinflammatory and antielastase properties and enhances penetration of antibiotics into bronchial mucus.

Erdosteine is a mucolytic. Erdosteine was developed for the treatment of chronic obstructive bronchitis.

Safety

• Symbol(GHS): GHS07
• Signal word: Warning
• Hazard statements: H302-H315-H320-H335
• Precautionary statements: P261-P280-P301+P312-P302+P352-P305+P351+P338
• RTECS: AJ1476200
• HS Code: 2934.99.9001
• Toxicity: LD50 in mice and rats (g/kg): >10 orally; >3.5 i.v. (Gonella)